Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Feb 24, 2019 11:07am
76 Views
Post# 29405771

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RBC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RBCI thought the original explanation given for delaying F4 was along the lines that the wanted to run down and manage the original formulation stocks.

Maybe the earlier manufacturing blunder has pushed them to a much more conservative approach that keeps the old formulation stock high enough to cover any eventualities that might arise from the introduction of F4. If they are doing stability testing there is always a possiblity (however small) the testing throws up a problem (after all thats the point of doing the testing). Maybe they are covering their backs better this time, ensuring the older formulation covers any problem period and they dont end up with a period of no stock. That might lead to a longer introduction time, idk. Do we know if any actual problems have been encountered? I actually missed the first 10mins of the cc, I'll listen again, did they say there was going to be an added delay?

palinc2000 wrote: Poor
can you offer an explanation as to why the F4 formulation which was approved last fall by FDA wont be made available until Oct at the earliest?


Bullboard Posts